Literature DB >> 7892601

Tyrosine kinase inhibition: an approach to drug development.

A Levitzki1, A Gazit.   

Abstract

Protein tyrosine kinases (PTKs) regulate cell proliferation, cell differentiation, and signaling processes in the cells of the immune system. Uncontrolled signaling from receptor tyrosine kinases and intracellular tyrosine kinases can lead to inflammatory responses and to diseases such as cancer, atherosclerosis, and psoriasis. Thus, inhibitors that block the activity of tyrosine kinases and the signaling pathways they activate may provide a useful basis for drug development. This article summarizes recent progress in the development of PTK inhibitors and demonstrates their potential use in the treatment of disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7892601     DOI: 10.1126/science.7892601

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  284 in total

1.  Contractile actions of proteinase-activated receptor-derived polypeptides in guinea-pig gastric and lung parenchymal strips: evidence for distinct receptor systems.

Authors:  M Saifeddine; B Al-Ani; S Sandhu; S J Wijesuriya; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 2.  Protein kinases as therapeutic targets.

Authors:  R Sridhar; O Hanson-Painton; D R Cooper
Journal:  Pharm Res       Date:  2000-11       Impact factor: 4.200

Review 3.  Regulators of vascular permeability: potential sites for intervention in the treatment of macular edema.

Authors:  M C Gillies
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

4.  The tyrosine kinase inhibitor tyrphostin AG126 reduces the development of acute and chronic inflammation.

Authors:  S Cuzzocrea; M C McDonald; E Mazzon; D Siriwardena; G Calabrò; D Britti; G Mazzullo; A De Sarro; A P Caputi; C Thiemermann
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

Review 5.  Receptor imaging in breast carcinoma: future prospects.

Authors:  C Van de Wiele; S Van Belle; G Sleghers; R A Dierckx
Journal:  Eur J Nucl Med       Date:  2001-06

6.  Synergistic induction of cyclooxygenase-2 by transforming growth factor-beta1 and epidermal growth factor inhibits apoptosis in epithelial cells.

Authors:  D Saha; P K Datta; H Sheng; J D Morrow; M Wada; H L Moses; R D Beauchamp
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

7.  Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.

Authors:  A E Lenferink; J F Simpson; L K Shawver; R J Coffey; J T Forbes; C L Arteaga
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

8.  The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export.

Authors:  S H Hong; M L Privalsky
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

9.  Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy.

Authors:  P Vajkoczy; M D Menger; B Vollmar; L Schilling; P Schmiedek; K P Hirth; A Ullrich; T A Fong
Journal:  Neoplasia       Date:  1999-04       Impact factor: 5.715

10.  Receptor tyrosine kinase inhibitors that block replication of influenza a and other viruses.

Authors:  Naveen Kumar; Nishi R Sharma; Hinh Ly; Tristram G Parslow; Yuying Liang
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.